AtheroGene
Initiatives
-
The objectives of the AtheroGene study:
* To assess the value of clinical and molecular biomarkers for secondary prevention in patients with coronary artery disease.
* To assess risk prediction across a wide range of coronary artery disease phenotypes with particular emphasis on the role of genetics.
* The major endpoint in this study was cardiovascular death and non-fatal myocardial infarction among other cardiovascular outcomes.
- Start Year
- 1996
- End Year
- 2004
- Funding
- Stiftung Rheinland-Pfalz für Innovation, Ministry for Science and Education, Mainz, Germany (AZ 15202-386261/545); INSERM, Paris (to Dr. Blankenberg), and the Schleicher Stiftung, Dresdner Bank, Frankfurt, Germany.
Visit AtheroGene
| Investigators | Contacts |
|---|---|
|
|
Design
- Study design
- Population cohort
- Follow Up
- Median follow-up period of 4.2 years
Marker Paper
Zengin E, Bickel C, Schnabel RB, Zeller T,Lackner K-J, Rupprecht H-J, et al. (2015) Risk Factors of Coronary Artery Disease in Secondary Prevention—Results from the AtheroGene—Study. PLoS ONE 10(7): e0131434. doi:10.1371/journal.pone.0131434
Recruitment
- Sources of Recruitment
-
- Individuals
Number of participants
- Number of participants
- 3,229
- Number of participants with biosamples
- Supplementary Information
- Patients with suspected coronary artery disease
Access
Availability of data and biosamples
| Data | |
| Biosamples | |
| Other |